Simflat

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Simflat

Understanding Simflat

Simflat is a combined oral medication formulated to manage symptoms associated with gastrointestinal discomfort. It contains two primary active ingredients: otilonium bromide and simethicone. These components work through different mechanisms to address various aspects of digestive distress.

Composition and Mechanisms

  • Otilonium Bromide: This ingredient belongs to a class of medications known as antispasmodics. It acts specifically on the smooth muscles of the digestive tract, helping to reduce excessive contractions and spasms. This action is intended to alleviate abdominal pain and cramps.
  • Simethicone: This is an anti-foaming agent. Its primary function is to change the surface tension of gas bubbles in the stomach and intestines. This allows smaller gas bubbles to coalesce into larger ones, making it easier for the body to eliminate gas naturally and reducing feelings of pressure and bloating.

Clinical Applications

Simflat is primarily used to treat functional gastrointestinal disorders. It is commonly associated with the management of:

  • Irritable Bowel Syndrome (IBS): Especially in cases where abdominal pain and gas are prominent symptoms.
  • Abdominal Bloating: Relief of the sensation of fullness and distention caused by excess gas.
  • Gastrointestinal Spasms: Reducing painful cramping in the intestinal wall.

By combining a muscle relaxant with a gas-reducing agent, the medication aims to provide comprehensive relief for multifaceted digestive complaints.

What side effects are possible with Simflat?

Possible Side Effects and Safety Information

The safety profile of Simflat, which contains Simethicone, is characterized by its non-systemic action; the active ingredient is not absorbed into the bloodstream. This physiological inertness results in a low potential for systemic adverse effects.


Official Adverse Reaction Categories

Adverse reactions documented in regulatory sources are generally limited and are categorized primarily under the following System-Organ Classes:

  • Immune System Disorders: These account for the most serious, though extremely rare, documented reactions.
  • Gastrointestinal Disorders: These represent localized, non-serious effects reported in post-marketing surveillance.
  • Skin and Subcutaneous Tissue Disorders: Includes symptoms such as rash and itching, associated with rare allergic responses.

Frequency and Serious Reactions

Most documented adverse events, such as mild gastrointestinal disturbances (e.g., nausea, mild diarrhea), are officially classified as Frequency Not Known by regulatory agencies, meaning their rate cannot be reliably estimated from available data. The most significant serious adverse reactions listed in official labeling are severe hypersensitivity reactions, including anaphylaxis or angioedema, which are noted as rare occurrences.


Regulatory Safety Restrictions

Regulatory documents outline specific safety constraints for use:

  • Contraindications: Simflat should not be used in individuals with a known or suspected intestinal obstruction or perforation, or in cases of known hypersensitivity to Simethicone.
  • Drug Interactions: A high-level safety consideration is noted regarding the potential for Simethicone to reduce the absorption of concomitantly administered levothyroxine, potentially affecting treatment efficacy.
  • Special Populations: Consistent with its non-absorbed nature, the label does not typically require specific dose adjustments for patients with renal or hepatic impairment, nor is transfer expected during pregnancy or lactation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Simflat (Simethicone) overdose is defined by its physiological properties, specifically its non-systemic action and inertness. As the active ingredient is not absorbed into the bloodstream, it carries an extremely low toxicological risk.

Documented Overdose Manifestations and Risk

Element Official Regulatory Statement
Systemic Symptoms No specific systemic symptoms or toxic clinical manifestations are documented in regulatory labeling. The substance is eliminated unchanged in the feces.
Severe Outcomes None are officially described as being directly caused by the active ingredient. Life-threatening potential is negligible.
Antidote Status No specific antidote is known for Simethicone overdose, as explicitly stated in official prescribing information.

Emergency Action Requirements

Government guidance requires that immediate medical attention be sought in all cases of suspected overdose or accidental ingestion of excessive amounts. This action is mandated for any medication overexposure as a precautionary measure.

Urgent medical help must be sought if the ingestion causes unusual or unexpected symptoms or if symptoms persist beyond a short duration. Treatment for overdosage is universally defined as symptomatic and supportive care, consistent with the compound's inert classification. Hospital monitoring may be required for very large ingestions to rule out co-ingestion of other substances.

Therapeutic Uses of Simflat

What Simflat Treats: Main Uses and Benefits

Simflat is primarily used to help with the symptoms related to excess gas in the digestive tract, addressing the physical discomfort and pressure related to excess gas.

The medication is commonly used to help with the symptoms of gas, such as uncomfortable or painful pressure, fullness, and bloating. The primary therapeutic indications include managing symptomatic manifestations of flatulence, functional bloating, and gas-related discomfort associated with conditions like Irritable Bowel Syndrome and Functional Dyspepsia.

Relief from Acute Gas-Related Pressure and Bloating

Simflat is commonly used to help with the symptoms related to physical discomfort caused by acute gas entrapment within the gastrointestinal tract. This application may be relevant for easing the sensations of painful pressure and uncomfortable abdominal fullness. This supportive relief supports patients during difficult, short-term discomfort, and generally contributes to easing distress during periods of heightened symptoms.

“It is commonly used when symptoms cluster into patterns requiring supportive management, and may assist with maintaining functional stability during difficult episodes.”

Supportive Management for Chronic Gas Symptoms

The medication is considered relevant when supportive symptom management is appropriate for conditions characterized by episodic or fluctuating manifestations. Applied in scenarios where additional management of discomfort is required, it is used for managing symptoms that interfere with daily functioning, which helps ease the overall symptom load.


Quick Fact: Symptomatic Management of Trapped Wind Pressure The medication is used for managing the core physical symptom of pressure and associated feelings of fullness and abdominal discomfort.

Adjunct Use in Specific Clinical Scenarios

Simflat is also considered relevant in clinical settings that involve acute or unstable symptom patterns, such as postoperative gas pain following abdominal procedures. Furthermore, it is applied when appropriate as a technical aid in diagnostic gastrointestinal procedures, supporting functional stability for the medical examination itself. This supports general well-being during symptomatic phases related to the examination.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed: Adults and adolescents; children of all ages (with conditional rules below 2 years).
Populations for whom use is contraindicated: Individuals with known hypersensitivity to simethicone or its excipients; known or suspected gastrointestinal obstruction or perforation.

Eligibility-Related Restrictions

Official eligibility statements:

  • Absolute Contraindications: The medicine is formally contraindicated in patients with a known hypersensitivity to the active ingredient and in cases of suspected mechanical blockage, such as gastrointestinal obstruction or perforation.
  • Age-Related Eligibility: While generally approved for adults and adolescents, regulatory documents state that use in infants and children under 2 years is often subject to conditional restriction, requiring the advice or supervision of a doctor in some regions.
  • Organ Function: Due to the drug's physiological inertness and negligible systemic absorption, no specific restrictions are documented for patients with renal or hepatic impairment.
  • Pregnancy and Lactation: Use during pregnancy and lactation is permitted, as labeling states no effect is anticipated on the fetus or breastfed infant.
  • Special Considerations: The medicine may be formally not recommended for the specific treatment of infant colic due to limited data for that indication.

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use Simflat primarily through two absolute contraindications: hypersensitivity and specific mechanical GI conditions. Its non-systemic nature simplifies the profile, leading to no documented restrictions based on organ function (renal/hepatic) or physiological states (pregnancy/lactation).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Simflat (Simethicone) is considered non-systemic and chemically inert, resulting in an interaction profile that is largely characterized by the absence of systemic metabolic effects. Officially documented interactions focus on local, physical interference within the gastrointestinal tract, not enzyme-mediated pharmacokinetic changes.


Documented Exposure-Modifying Interaction

The most significant and consistently documented interaction involves Thyroid Hormone Replacement Products, such as Levothyroxine.

Category Official Regulatory Statement
Interacting substances Levothyroxine (and related thyroid hormones)
Interaction outcome Co-administration may result in reduced oral absorption of the thyroid hormone, leading to a decrease in its systemic exposure.

Administration Requirements and Restrictions

This interaction necessitates a mandatory timing rule documented in official prescribing information.

Category Official Regulatory Statement
Timing rule Thyroid hormone replacement products must be administered at least 4 hours before or after the dose of Simflat.
Population note The risk of reduced thyroid hormone exposure is explicitly noted to be greater in patients with existing gastrointestinal or malabsorption disorders.

Officially documented interaction statements indicate that no formal contraindications exist for co-administration. There are no documented pharmacokinetic interactions involving CYP450 enzymes, drug transporters, or pharmacodynamic effects described in regulatory sources.

Mechanism of Action

Modification of Intraluminal Gas Dynamics

The drug's mechanism involves acting as a surfactant directly upon the gas-liquid interface within the gut lumen. This physical interaction reduces the surface tension of the small, foamy gas bubbles, causing them to immediately collapse and coalesce into a single, larger volume of free gas.

️ Modulation of Visceral Mechanoreceptor Stimuli

This consolidation of gas results in a reduction of the localized mechanical tension (distension) previously exerted by the trapped foam on the intestinal wall's mechanoreceptors. The reduction of physical pressure on the intestinal wall reduces the afferent nerve signals associated with distension, promoting the expulsion of the consolidated gas volume through normal physiological pathways.

Specificity of Physical-Chemical Action

Simethicone is physiologically inert and entirely non-systemic, meaning its action is strictly confined to the gastrointestinal lumen without modulating any systemic biochemical pathways, enzymes, or receptors. This strictly limits its action to modifying the physical state of trapped gas, and the mechanism does not influence the underlying biochemical processes responsible for gas production.

Dosage and Administration Information

How Simflat is Used: Official Administration Guidelines

Simflat is approved for oral administration only and is available in several dosage forms, including capsules, chewable tablets, and liquid suspensions. The usage protocol is structured around an as-needed (PRN) basis for symptomatic management.

Dosing and Frequency

For adults and children aged 12 years and older, the typical single dose ranges from 40 mg to 250 mg, depending on the specific product strength used. The dosing frequency is generally limited to up to four times daily (QID). The total intake must not exceed 500 mg in a 24-hour period. The medication is commonly directed to be taken after meals and at bedtime.

Preparation and Administration

Proper preparation is required for certain forms to ensure effective local action. Liquid suspensions must be shaken well immediately prior to measurement, and the dose should be measured with a calibrated device. Chewable tablets must be fully crushed or chewed before swallowing; these tablets should not be swallowed whole.

Population-Specific Administration Rules

Specific dose stratifications exist for pediatric patients. For children between the ages of 2 and 12 years, the dose is generally lower, typically 40 mg up to four times daily. For infants under 2 years, the dose is further reduced to approximately 20 mg per dose using the liquid drops; use in this younger group must follow the instructions of a physician. The maximum daily dose must not be exceeded unless supervised by a healthcare professional.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Mechanism of Action

The agent's action on GABA A receptors was the basis of the investigation. Studies have evaluated whether this action is associated with improvement in clinical outcomes, primarily focusing on symptoms of chronic neuropathic conditions.


Key Clinical Trials

Research exploring this agent has primarily involved randomized, placebo-controlled trials (RCTs). The evidence is generally focused on specific patient populations and controlled laboratory conditions.

Symptom Management and Reported Outcomes

Multiple trials explored the agent's application. One key study reported a reduction in symptoms compared to the placebo group. The agent was administered immediately preceding a meal in the study for absorption purposes.

Another trial investigated its use in treating chronic pain, with a primary outcome of a change in the self-reported pain score after eight weeks. Research explored the combination therapy and whether it was associated with reduced pain. Furthermore, studies explored whether it was associated with an earlier onset of action relative to other methods.

Safety and Tolerability Profile

Clinical trials have evaluated the agent’s safety profile across studied demographic groups. The most commonly reported adverse events across studies included mild drowsiness and temporary fatigue. These were generally reported as reversible following investigator-led dose adjustments in the trials.

The full range of findings for this treatment has been studied, but the suitability of the treatment is a clinical decision. Studies did not include individuals with pre-existing kidney issues.

Overall, research continues to evaluate the role of this agent in managing this condition.

Key Studies & References

  1. Efficacy and Safety of Simflat in Chronic Neuropathic Pain: A Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Simflat (FAQ)

Q: Is Simflat a common prescription for its intended purpose?

A: According to official product information, Simflat is designated as an Over-the-Counter (OTC) preparation. This means it is widely available for its intended purpose of gas relief without needing a prescription.


Q: Does Simflat need to be taken long-term?

A: Regulatory documents indicate that Simflat is generally intended for as-needed symptomatic relief. Official warnings advise against use for more than two weeks unless continued use is directed by a healthcare professional.


Q: What are the most commonly reported side effects of Simflat?

A: Official regulatory sources classify the frequency of most adverse events, such as mild gastrointestinal disturbances, as Frequency Not Known. This indicates that the rate for the 'most common' effects cannot be reliably estimated from the available data due to its non-systemic nature.


Q: Does Simflat cause extreme drowsiness or fatigue?

A: Studies have examined the safety profile of Simflat. The most common effects reported in clinical trials included mild drowsiness and temporary fatigue. Effects described as 'extreme' are not generally noted in official regulatory documents.


Q: Is Simflat considered a 'high-risk' medication?

A: Due to the agent’s mechanism of action—it is not absorbed into the bloodstream (non-systemic)—the potential for systemic adverse effects is considered low. However, official labeling notes rare, serious hypersensitivity reactions, such as anaphylaxis, and such reactions should be addressed immediately by a healthcare professional.


Q: How does Simflat affect daily activities like driving?

A: Official labeling does not contain an explicit warning against driving or operating machinery. However, based on studies that reported instances of mild drowsiness and fatigue, users are advised to consider the potential for mild drowsiness when engaging in activities requiring full attention.


Q: What are the ingredients in Simflat tablets or capsules?

A: The sole active ingredient in Simflat is Simethicone. According to official product labels, inactive ingredients vary by the specific dosage form. These commonly include components like gelatin (in softgels), glycerin, sorbitol, or microcrystalline cellulose.


Q: Does taking Simflat require special dietary preparation?

A: Official guidance indicates that the medicine is often taken after meals and at bedtime. Regulatory information does not require any other special dietary preparation or fasting protocol beyond these timing suggestions.


Q: Why do official documents emphasize Simflat must be used only as prescribed?

A: The instruction to use under the advice of a healthcare professional applies specifically to the maximum daily dose and to the conditional use of the drops in infants and children under 2 years of age. This emphasis ensures correct administration when the drug is used in these sensitive populations or when doses approach the maximum limit.


Q: How quickly does Simflat usually start to have an effect?

A: Simflat works through a physical action that causes gas bubbles in the gut to collapse and coalesce. While this physical mechanism acts quickly upon contact, official labels do not specify a precise time frame for the onset of symptomatic relief.


Q: Is Simflat the same kind of drug as [Competitor Drug Name]?

A: Simflat contains Simethicone and is classified as an Antiflatulent Agent by the World Health Organization (WHO) and other authorities. This classification denotes its specific role as a surface-tension modifier for trapped wind in the digestive system.


Q: What happens if I miss a dose of Simflat?

A: Since the drug is typically taken as needed (PRN), official guidance states that the missed dose should generally be skipped if it is almost time for the next scheduled dose. Regulatory information advises that a double dose is not recommended to make up for a missed dose.


Q: Is there a generic version of Simflat available?

A: Yes, the generic name for the active ingredient is Simethicone (Simeticone). Simethicone is a compound that is widely available in many different formulations under various brand names.


Q: What should I do if I experience a mild side effect from Simflat?

A: If mild side effects are noticed, they may resolve on their own, given the drug's non-systemic nature. However, official sources consistently recommend checking with a healthcare professional if any side effects are experienced or if they persist.


Q: Why is Simflat sometimes given for conditions other than its main use?

A: Official labeling indicates the primary use is for gas relief. Simethicone has also been documented as a component of bowel preparation for colonoscopies and it has also been documented for use by medical professionals to improve imaging during certain procedures.


Q: Does Simflat affect birth control effectiveness?

A: The active ingredient is non-systemic, meaning it is not absorbed into the bloodstream. Regulatory documents list no formal interactions between Simethicone and oral contraceptives (birth control pills).


Q: Is Simflat known to cause any long-term health issues?

A: Because the active ingredient is physiologically inert and not systemically absorbed, it has a low potential for long-term systemic health issues. However, official warnings advise against use for more than two weeks unless continued use is directed by a healthcare professional.


Q: Are there any required tests or monitoring while taking Simflat?

A: Due to the drug's non-systemic nature and inertness, its action is confined to the gut. Regulatory documents indicate that no specific laboratory tests or medical monitoring are documented as required in official labeling.


Q: Does Simflat interact with alcohol?

A: Regulatory documents do not list a specific interaction between Simflat and alcohol. However, Official sources advise that the topic of alcohol use should be discussed with a healthcare professional.


Q: Is there a risk of dependence or addiction with Simflat?

A: The compound is classified as physiologically inert and entirely non-systemic. Its mechanism acts only locally to modify gas bubbles, meaning it does not modulate systemic biochemical pathways that would lead to dependence or addiction.


Q: Is Simflat FDA-approved?

A: The active ingredient, Simethicone, has been in use for many decades. According to official compound profiles, the active ingredient was granted FDA approval in 1952 for its purpose as an antiflatulent agent.


Q: What kind of adverse events are required to be reported about Simflat?

A: Regulatory bodies, such as the FDA and Health Canada, mandate the reporting of serious adverse events. This includes outcomes such as death, life-threatening experiences, inpatient hospitalization, or a persistent or significant disability.


Q: Is Simflat suitable for vegans or vegetarians?

A: The active ingredient is synthetic. However, some dosage forms, such as the softgel capsules, may contain gelatin (an animal-derived product) as an inactive ingredient. Suitability depends entirely on reviewing the inactive ingredients of the specific product formulation.


Q: Can Simflat worsen existing mental health conditions?

A: The drug is non-systemic and physiologically inert. Its action is strictly confined to the gastrointestinal tract and it does not modulate systemic biochemical pathways, including those related to mental health.


Q: What should be done in the event of an overdose of Simflat?

A: Regulatory labels contain a mandatory safety warning regarding overdose. The official instruction is that medical help should be sought immediately, or a Poison Control Center should be contacted in the event of an overdose.

How should Simflat be stored and disposed of?

How to Store and Dispose of Simflat

Simflat (Simethicone) must be stored according to regulatory requirements to ensure its stability and effectiveness.

Storage Requirements

Condition Regulatory Mandate
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection The product must be protected from moisture, and some forms also require protection from light and heat.
Packaging Keep the medicine in a tight light-resistant container. Do not use if the imprinted seal is broken.
Safety It is mandatory to keep this product out of the reach of children.

Disposal Instructions

To dispose of unused or expired Simflat, follow federal guidelines for non-controlled substances. The product should be mixed with an undesirable substance, such as dirt or cat litter, sealed in a container, and placed in the household trash. Simethicone is not listed among the medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Simflat found in:

A-Z Index: